Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Cyclopentanohydrophenanthrene ring system DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions


Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514171000 With additional active ingredient 552
514177000 Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system 326
514172000 Hetero ring containing 220
514182000 Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system 163
514170000 Plural Compounds containing cyclopentanohydrophenanthrene ring systems 161
20110190243DIAGNOSIS AND TREATMENT OF BACK PAIN - The present invention relates to methods of diagnosing and/or treating lower back pain (LBP). In one embodiment, the invention relates to a system for diagnosis of a form of lower back pain in an individual, using a means to identify a type and/or a concentration of one or more inflammatory mediators in the epidural space of the individual. In another embodiment, the invention relates to a system for diagnosis of a form of lower back pain in an individual by identifying a type and/or concentration of one or more inflammatory mediators in the epidural space of the individual, and rendering a diagnosis of the form of lower back pain in the individual based on the presence, absence and/or combination of presences and/or absences of one or more inflammatory mediators in the epidural space of the individual08-04-2011
20080261927Stable Aqueous Suspension - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.10-23-2008
20130065868ANXIOYTIC MARCGRAVIACEAE COMPOSITIONS CONTAINING BETULINIC ACID, BETULINIC ACID DERIVATIVES, AND METHODS - Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.03-14-2013
20110021471REDUCING Abeta42 LEVELS AND Abeta AGGREGATION - This document relates to methods and materials for reducing Aβ42 levels, reducing Aβ aggregation, or reducing both Aβ42 levels and Aβ aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5β-cholanic acid) to reduce Aβ42 levels and to reduce Aβ aggregation in mammals.01-27-2011
20100267680USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS - The invention relates to the use of at least one oxime derivative of cholest-4-en-3-one as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.10-21-2010
20100160268Isoflavonoid Analogs and their Metal Conjugates as Anti-Cancer Agents - A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.06-24-2010
20100035851AGENT FOR IMPROVING INSULIN RESISTANCE - To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains a compound having a cyclolanostane skeleton, or an organic solvent extract, a hot water extract of a plant of the family Liliaceae or Gramineae, or a fraction thereof which contains the compound as an active ingredient.02-11-2010
20110172196PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.07-14-2011
20090197841Inhalant Propellant-Free Aerosol Formulation - The invention relates to inhalant propellant-free aerosol formulations containing at least one inert, non-volatile auxiliary substance for adjusting defined droplet sizes.08-06-2009
20130190277Paraffin Wax Embedded Drug Delivery System - A paraffin wax embedded drug delivery system is a method for combining topical medications with paraffin wax for enhanced delivery and absorption of the topical medication at a treatment area on a human body. A quantity of paraffin wax and a topical medication are provided, and mixture measurements are specified for a desired concentration and a desired ratio of ingredients for the mixture. To combine the topical medication and the paraffin wax, the quantity of paraffin wax is heated, the topical medication is added to the liquid paraffin wax, the mixture is agitated to ensure even combination, and the mixture is cooled. To apply the mixture, the mixture is heated back to its liquid state and applied to a treatment area using a wax bath, a brush, a roller, or another method.07-25-2013
20100216752USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS - A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I08-26-2010
20120142644METHOD FOR PRODUCING PHYTOSTEROL/PHYTOSTANOL PHOSPHOLIPID ESTERS - The present invention relates to a method of producing a phytosterol ester and/or a phytostanol ester comprising: a) admixing a phospholipid composition comprising at least between about 10% to about 70% plant phospholipid and at least about 5% water; a lipid acyltransferase; and a phytosterol and/or a phytostanol; and b) separating or isolating or purifying at least one phytosterol ester and/or phytostanol ester from said admixture. The present invention also relates to compositions comprising the phytosterol ester and/or phytostanol ester produced by this method, including foodstuffs and personal care product (cosmetic) compositions.06-07-2012
20090325911Use of Androgens for the Treatment of Parkinson's Disease - The invention generally provides therapeutic and prophylactic methods relating to the use of androgens for the treatment of Parkinson's disease or other neurodegenerative diseases. In addition, the invention provides related methods of screening for compounds for the treatment of Parkinson's disease.12-31-2009
20090247492MANGANESE BASED ORGANOMETALLIC COMPLEXES, PHARMACEUTICAL COMPOSITIONS AND DIETETIC PRODUCTS - The invention relates to compounds and their uses, particularly in the pharmaceutical and dietetic industries. The invention discloses complexes having Mn-SOD like activities, as well as methods for treating various diseases associated with oxidative stress, including cancer and inflammatory conditions, by administering said compounds. It further deals with pharmaceutical compositions or dietetic products comprising said compounds, more particularly useful to treat various diseases or disorders, in particular useful in the prevention or treatment of a disease involving an oxidative stress.10-01-2009
20090062243Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof - The present invention comprises lupine-type triterpenoids that inhibit cell proliferations, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.03-05-2009
20090105199OLIGOMERS OF CHOLESTEROL, CHOLESTEROL SULPHATE AND CHOLESTEROL ESTERS AND ALSO DRUGS CONTAINING THESE - The invention relates to new substances which are derived from cholesterol, cholesterol sulphate and cholesterol esters of a natural, semi-synthetic or synthetic origin in that they represent oligomers with a specific type of cross-linkage of the starting substances based on cholesterol.04-23-2009
20090186861Process for Production of Fatty Acids, Fatty Acid Esters and Sterolesters from Soapstock - The invention relates to a process for production of fatty acids directly from soapstock generated in the alkali refining process including the steps of (a) adding a lipase directly to the alkaline soapstock to facilitate hydrolysis of glycerides without prior neutralisation, (b) neutralizing and splitting the soaps with strong acids, and (c) separating the fatty acid phase from the aqueous phase by settling and/or centrifugation. A second embodiment is a process in which the soapstock is first neutralized and split with strong acids, followed by adding a lipase to facilitate glyceride hydrolysis, and separating the fatty acid phase. The fatty acids so obtained can be esterified with C1-C6 alcohols using a lipase that is selective for fatty acids and does not transesterify the sterolesters, and the fatty acid esters and sterolesters are separated by distillation.07-23-2009
20100184731TREATMENT OR PREVENTION OF HYPERTENSIVE DISORDERS OF PREGNANCY OR FETAL GROWTH RETARDATION - The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R07-22-2010
20130217656METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LUPUS - The present invention relates to methods, compositions, and diagnostic tests for diagnosing and treating lupus and other related diseases or disease subsets. In particular, the method, compositions, and diagnostic tests relate to a combination of one or more genes, where the expression of these genes indicates a predisposition to develop, or a diagnosis of, lupus and other related diseases or disease subsets.08-22-2013
20120135969NOVEL POWDERED CRYSTALLINE MEDICINES FOR INHALATION - The invention relates to manufacturing processes for preparing inhalable powders, and to the stable crystalline inhalable powders prepared by this process. Similarly, the invention relates to the use of these inhalable powders for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.05-31-2012
20110251162METHODS OF TREATMENT FOR MRSA INFECTIONS - The present subject matter relates to pathogenesis of MRSA. Specifically, the present disclosures identifies the pro-inflammatory properties of PVL as the cause of MRSA. Viewed from this new perspective, the present subject matter achieves novel methods and apparatus for treating MRSA infection in a subject involving the administration of an anti-inflammatory drug to the subject. Furthermore the present subject matter teaches methods and apparatus for treating a Panton-Valetine leukocidin associated infection in a subject involving the administration of an anti-inflammatory drug to the subject.10-13-2011
2012030253023-HYDROXY-BETULINIC ACID DERIVATIVES, PREPARATION METHODS AND USES THEREOF - The present invention discloses 23-hydroxyl-betulinic acid derivatives, including 3-oxo-23-hydroxyl-betulinic acid, 3-oxo-23-hydroxyl-dihydrobetulinic acid, and 23-hydroxyl-dihydrobetulinic acid. The present invention also discloses the preparation methods thereof and medical applications as anti-tumor and anti-HIV agents.11-29-2012
20080287404High Purity 17Alpha-Cyanomethyl-17Beta-Hydroxy-Estra-4,9-Diene-3- One and Process For the Syntheses Thereof - The invention relates to a new process for the synthesis of high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents. According to our invention the dienogest of formula (I) is synthesized the following way: i) 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) is reacted with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating; ii) the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV) is reacted with cyanomethyl lithium at a temperature between 0 and −30° C.; iii) the obtained 3-methoxy-17α-cyanomethyl-17β-hydroxy-estra-2,5(10)-diene of formula (III) is reacted with a strong organic acid in tetrahydrofuran solution; iv) the obtained 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-one of formula (II) is reacted with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60° C., then the obtained crude dienogest of formula (I) is purified by recrystallization and preparative HPLC.11-20-2008
20120309720COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.12-06-2012
20120309721METHOD FOR PROVIDING NEUROPROTECTION - A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I12-06-2012
20100216751Liquid Bevirimat Dosage Forms for Oral Administration - The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.08-26-2010
20100137263ASSAY FOR THE DETECTION OF BIOMARKERS ASSOCIATED WITH PREGNANCY RELATED CONDITIONS - The invention relates to screening methods for determination of the risk of preterm delivery and/or pregnancy associated conditions. The methods involve detection of the level of one or more biomarkers in a biological sample from the patient. In particular, in embodiments of the invention there are provided methods for determining the risk of pre-eclampsia and other hypertensive disorders, and intrauterine growth retardation (IGUR).06-03-2010
20110071121DIAGNOSIS AND/OR PROGNOSIS OF RENAL DYSFUNCTION - The present invention relates to a method for diagnosing and/or prognosing renal dysfunction. The method comprises the steps of:—(a) determining the level of an anti-inflammatory cytokine present in a urine sample from a subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic shock syndrome; (b) determining the level of the anti-inflammatory cytokine present in a urine sample from the subject following physical trauma, following or during a hypotensive event, following or during sepsis, and/or following or during septic shock syndrome; (c) calculating the difference between the level of the anti-inflammatory cytokine determined in step a) from the level of the anti-inflammatory cytokine determined in step b), and (d) providing a diagnosis and/or prognosis on the basis of a comparison between the difference calculated in step c) and the difference calculated in step c) when steps a) and b) are practiced on a control group.03-24-2011
20120316141METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY - A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I12-13-2012
20120172342Biotherapeutics For the Treatment of Infectious Diseases - An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.07-05-2012
20120178725METHOD OF MODULATING SHIP ACTIVITY - A method of treating or preventing an immune disorder, such as graft versus host disease, in a subject. The method includes the administering a SHIP1 inhibitor, such as 3α-aminocholestane, to a subject in need of treatment. Thus, SHIP1 inhibitors taught herein represent a novel class of small molecules that have the potential to enhance allogeneic transplantation, boost innate immunity and improve the treatment of hematologic malignancies.07-12-2012
20100305078METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES - The presently disclosed subject matter is directed to metallo-oxidoreductase inhibitors having metal binding moities linked to a targeting moiety through a linking group or a direct bond, methods for screening for metallo-oxidoreductase inhibitors, and methods of treating an oxidoreductase related disorder by administering a metallo-oxidoreductase inhibitor to a subject in need of treatment thereof.12-02-2010
20100292195LOW BURST POLYMERS AND METHODS TO PRODUCE POLYMER - A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.11-18-2010
20110046094METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS - A unique set of genetic variations associated with lupus are provided. Also provided are methods for detecting such genetic variations and for assessing risk of developing lupus as well as for diagnosing and treating lupus.02-24-2011
20080227760Method of Extracting Ginsengnoside Rg2m, Pharmaceutical Composition Including Ginsengnoside Rg2, and Uses Thereof - The present invention provides a method of extracting ginsenoside Rg09-18-2008
20130096094Derivatives of 3-O-(3',3'-dimethylsuccinyl)-betulinic acid - The present invention relates to compounds of the following formula (I):04-18-2013
20080200439Methods and compositions for modulating BK channel activity and vasodilation - Methods and compositions are provided for modulating myocyte BK channel activity and for screening for modulators of BK channel activity. The methods and compositions are useful in the treatment of disorders where increasing myocyte BK channel activity can attenuate, revert or prevent the disorder. For example, the methods and compositions are useful for treating disorders ameliorated by increasing vasodilation and blood flow in a subject, in particular, increasing cerebral blood flow.08-21-2008
20130203712METHODS FOR INHIBITING MUSCLE ATROPHY - In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.08-08-2013
20130203713POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USES - The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.08-08-2013

Patent applications in class Cyclopentanohydrophenanthrene ring system DOAI

Patent applications in all subclasses Cyclopentanohydrophenanthrene ring system DOAI